Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONCENTRAID vs PITRESSIN TANNATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CONCENTRAID is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and reduced heart rate.
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
Hypertension,Attention Deficit Hyperactivity Disorder (off-label)
Diabetes insipidus (central),Nocturnal enuresis (off-label),Variceal bleeding (off-label)
100 mg orally once daily, administered with or without food.
0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 8-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 20 hours in severe renal impairment (Cr Cl <30 m L/min), necessitating dose adjustment.
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Primarily hepatic via CYP2D6; also involves glucuronidation.
Metabolized primarily by the liver and kidneys via peptidases, with a half-life of about 10-20 minutes for vasopressin itself; the tannate formulation prolongs absorption.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose; fecal elimination via biliary excretion contributes 20-25%; the remaining 5-10% is metabolized and excreted renally as inactive metabolites.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Approximately 85-90% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein (AAG).
Negligible (<1%); mainly bound to plasma proteins primarily vasopressin-binding proteins and albumin, but binding is not clinically significant.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution and penetration into extravascular spaces.
Approximately 0.1 L/kg (range 0.08–0.12 L/kg). This low Vd indicates minimal tissue distribution, consistent with its predominant plasma volume confinement and renal clearance.
Oral: 75-85% (first-pass hepatic metabolism reduces bioavailability relative to IV); Intravenous: 100%; Intramuscular: 90-95%.
Intramuscular oil suspension: nearly 100% but with slow release. Subcutaneous: approximately 10–15% due to hydrolysis at injection site. Oral: negligible (<1%) due to enzymatic degradation.
GFR 30-89 m L/min: 50 mg once daily; GFR <30 m L/min: 25 mg once daily; hemodialysis: 25 mg three times weekly after dialysis.
Not significantly renally excreted; no specific dose adjustment recommended based on GFR.
Child-Pugh A: 75 mg once daily; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended.
No specific guidelines; use with caution in hepatic impairment due to potential fluid imbalance.
Not approved for pediatric use. In clinical trials, no safety data established.
0.1-0.3 m L (1-3 units) intramuscularly or subcutaneously, with dose adjusted based on response; monitor urine output and serum sodium.
No specific dose adjustment recommended; monitor renal function and consider lower starting dose (75 mg) due to age-related decline in renal function.
Start at lower end of dosing range (0.5 m L initially) due to increased risk of electrolyte disturbances and comorbid conditions; monitor serum sodium and fluid status closely.
None
None.
Rebound hypertension with abrupt discontinuation,Sedation and dizziness,Use in patients with cerebrovascular disease,Renal impairment
Hyponatremia and water intoxication; cardiac effects including arrhythmias and ischemia; mesenteric ischemia; hypersensitivity reactions; use with caution in patients with coronary artery disease, hypertension, or renal impairment.
Hypersensitivity to drug or components,Concomitant use with MAO inhibitors,Severe bradycardia or heart block
Hypersensitivity to vasopressin or components; anuria; chronic nephritis with nitrogen retention; cardiovascular disease (ischemic heart disease, advanced atherosclerosis, coronary thrombosis).
High-fat meals can delay absorption of immediate-release CONCENTRAID. Avoid excessive caffeine (coffee, tea, cola, energy drinks) as it may increase CNS stimulation and side effects. Grapefruit juice may potentiate effects; consider avoiding. No significant interaction with other foods.
Avoid excessive fluid intake beyond thirst to prevent water intoxication. Limit alcohol, which can inhibit vasopressin release and reduce drug efficacy. No specific food restrictions.
First trimester: Increased risk of neural tube defects and cardiac malformations (relative risk 2.0 based on registry data). Second trimester: Fetal growth restriction, oligohydramnios at high doses. Third trimester: Preterm labor, neonatal respiratory depression. Avoid in pregnancy unless benefit outweighs risk.
PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossification at high doses. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Vasopressin may cause uterine contractions and decrease placental perfusion, potentially leading to fetal hypoxia or distress, particularly in the third trimester.
Present in breast milk; M/P ratio 0.8. Limited data on adverse effects; caution advised. Monitor infant for somnolence and poor feeding. Use lowest effective dose.
It is unknown whether vasopressin is excreted in human breast milk. Due to its high molecular weight (tannate salt) and poor oral bioavailability, significant absorption by a nursing infant is unlikely. However, caution is advised. No M/P ratio is available.
Increased clearance in second and third trimesters (by 50-70%). Increase dose by 30-50% based on therapeutic drug monitoring; maintain trough levels at 5-10 mcg/m L. Postpartum: Reduce to prepregnancy dose within 48 hours.
No specific dose adjustments are established for pregnancy. However, because of increased plasma volume and renal clearance during pregnancy, lower serum concentrations may occur. Individualize dosing based on clinical response and avoidance of adverse effects such as hyponatremia and hypertension. Use the lowest effective dose.
CONCENTRAID (dexmethylphenidate) is a CNS stimulant used for ADHD. Monitor for hypertension, tachycardia, and growth suppression in children. Avoid in patients with glaucoma, motor tics, or a family history of Tourette's syndrome. Use with caution in patients with pre-existing psychosis, bipolar disorder, or substance abuse history. Immediate-release formulation has a rapid onset (30 min) and short duration (3-5 hours). Do not administer late in the day to avoid insomnia. Discontinue if seizures occur. Concomitant use with MAOIs is contraindicated within 14 days.
Pitressin Tannate is an aqueous suspension of vasopressin for intramuscular injection used for diabetes insipidus. Must be warmed and shaken vigorously before administration to ensure uniform suspension. Inject deeply IM into a large muscle; do not administer IV or subcutaneously. Onset is within 1-2 hours, duration 24-72 hours. Monitor for signs of water intoxication (headache, confusion, seizures) due to antidiuretic effect. Caution in coronary artery disease, hypertension, and renal impairment. Discontinue if abdominal cramps or nausea occur. Not for use in chronic nephrogenic diabetes insipidus.
Take exactly as prescribed, usually 2-3 times daily 4-6 hours apart. Do not crush or chew extended-release capsules.,Avoid taking with or after meals high in fat, as it may delay absorption.,Monitor blood pressure and heart rate regularly; report palpitations, chest pain, or shortness of breath.,Do not drive or operate machinery until you know how this medication affects you; it may cause dizziness or blurred vision.,Report any new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,Avoid alcohol and caffeine as they may exacerbate CNS stimulation.,Do not stop abruptly; taper under medical supervision to avoid withdrawal.,Inform your doctor of all medications, including OTC drugs, especially antidepressants, anticoagulants, and blood pressure medications.,May cause growth slowdown in children; regular height and weight checks are needed.,Store at room temperature, away from moisture and heat.
This medication is given as an injection into a muscle, usually every 1-3 days as prescribed.,Do not inject into a vein or under the skin; only into a muscle (buttock or thigh).,Warm the vial in your hands and shake it well just before use to mix the suspension evenly.,Drink only enough fluid to satisfy thirst; excessive fluid intake can lead to water intoxication.,Report any signs of water intoxication: severe headache, confusion, drowsiness, seizures, or difficulty breathing.,Avoid alcohol, which can interfere with the drug's effect and increase urine output.,Store the vial at room temperature away from light and do not freeze.,Monitor urine output and notify your doctor if it does not decrease or if side effects occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONCENTRAID vs PITRESSIN TANNATE, answered by our medical review team.
CONCENTRAID is a Antidiuretic Hormone Analog that works by CONCENTRAID is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and reduced heart rate.. PITRESSIN TANNATE is a Antidiuretic Hormone Analog that works by Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONCENTRAID and PITRESSIN TANNATE depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONCENTRAID is: 100 mg orally once daily, administered with or without food.. The standard adult dose of PITRESSIN TANNATE is: 0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONCENTRAID and PITRESSIN TANNATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONCENTRAID is classified as Category C. First trimester: Increased risk of neural tube defects and cardiac malformations (relative risk 2.0 based on registry data). Second trimester: Fetal growth restriction, oligohydram. PITRESSIN TANNATE is classified as Category C. PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossifi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.